APP inhibitors(Beta amyloid A4 protein inhibitors), PKCδ stimulants(Protein kinase C delta stimulants), PKCε stimulants(protein kinase C epsilon stimulants)

Therapeutic Areas

Immune System DiseasesNervous System DiseasesOther Diseases+ [2]

Active Indication

Alzheimer DiseaseMultiple SclerosisAcute Lymphoblastic Leukemia

Inactive Indication

Acinar Cell CarcinomaAdult Lymphoblastic LymphomaAdvanced cancer+ [41]

Originator Organization

Synaptogenix, Inc.

Active Organization

National Institutes of Health

Bryologyx, Inc.Startup

Synaptogenix, Inc.

Inactive Organization

National Cancer Institute

National Institute on Aging

Drug Highest PhasePhase 2

First Approval Date-

RegulationOrphan Drug (US)

Structure

Molecular FormulaC47H68O17

InChIKeyMJQUEDHRCUIRLF-UHFFFAOYSA-N

CAS Registry83314-01-6

Clinical Trials associated with Bryostatin 1

NCT06190912 / RecruitingPhase 1IIT

A Single-Arm, Single-Site, Single-Dose Phase 1 Study Assessing the Safety of Bryostatin in the Treatment of Patients with Multiple Sclerosis

This is a single-site, single-arm, single-dose, Phase 1 study of the safety of bryostatin in participants with multiple sclerosis (MS) receiving any disease modifying therapy (DMT).

Start Date26 Jun 2024

Sponsor / Collaborator

The Cleveland Clinic Foundation

[+1]

NCT04538066 / CompletedPhase 2

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing Safety, Tolerability and Long-term Efficacy of Bryostatin in the Treatment of Moderately Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment

To evaluate the safety, tolerability, and long-term efficacy of bryostatin 1 (hereafter referred to as bryostatin) for the treatment of moderately severe Alzheimer's disease (AD).

Start Date30 Aug 2020

Sponsor / Collaborator

Synaptogenix, Inc.

[+2]

NCT03560245 / CompletedPhase 2

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment

This is a randomized double-blind Placebo-controlled, Phase 2 study comparing bryostatin to placebo for the treatment of moderately severe to severe Alzheimer's disease in subjects not receiving memantine treatment. The study is 15 weeks in duration, including a safety and efficacy evaluation 30 days after the last dose of study drug. Subjects will receive 7 doses of study drug during the study. The primary efficacy endpoint is defined as the change from baseline to Week 13 in the Severe Impairment Battery (SIB) total score.

Start Date20 Jun 2018

Sponsor / Collaborator

Synaptogenix, Inc.

[+1]

100 Clinical Results associated with Bryostatin 1

100 Translational Medicine associated with Bryostatin 1

100 Patents (Medical) associated with Bryostatin 1

678

Literatures (Medical) associated with Bryostatin 1

01 Oct 2024·CELLULAR ONCOLOGY

Marine derived macrolide bryostatin 4 inhibits the TGF-β signaling pathway against acute erythroleukemia

Article

Author: Sun, Fan ; Li, Yi-Lin ; Leng, Jia-Rong ; Liu, Li-Yun ; Liu, Jie ; Yang, Fan ; Kou, Yan-Yu ; Lin, Hou-Wen ; Chang, Yung-Ting

PURPOSE:

Acute erythroleukemia (AEL) is a rare and highly aggressive subtype of acute myeloid leukemia (AML) with an extremely poor prognosis when treated with available drugs. Therefore, new investigational agents capable of inducing remission are urgently required.

METHODS:

Bioinformatics analysis, western blot and qRT-PCR were used to reveal the potential biological mechanism of bryostatin 4 (B4), an antineoplastic macrolide derived from the marine bryozoan Bugula neritina. Then, in vivo experiments were conducted to evaluate the role of transforming growth factor (TGF)-β signaling in the progression of AEL.

RESULTS:

Our results revealed that the proliferation of K562 cells and TF-1 cells was significantly inhibited by B4 at IC₅₀ values of 37 nM and 52 nM, respectively. B4 inhibited TGF-β signaling and its downstream pathway targets, particularly the phosphorylation of Smad2, Smad3, Ras, C-RAF, ERK1/2, and MEK. B4 also played an important role in cell invasion and migration in K562 cells and TF-1 cells by reducing the protein levels of the mesenchymal cell marker vimentin. Moreover, Flow cytometry and western blot analyses demonstrated that B4 induced apoptosis and initiated G0/G1 phase arrest by modulating mitochondrial dysfunction and cyclin-dependent kinase (CDK) expression.

CONCLUSION:

These findings indicated that B4 could inhibit the proliferation, migration, invasion, and TGF-β signaling pathways of AEL cells, thus suggesting that B4 possesses therapeutic potential as a treatment for AEL.

23 May 2024·BRIEFINGS IN BIOINFORMATICS

Unveiling promising drug targets for autism spectrum disorder: insights from genetics, transcriptomics, and proteomics

Article

Author: Sha, Weihong ; Zeng, Ruijie ; Huang, Wentao ; Lian, Qizhou ; Sun, Panpan ; Liu, Yufeng ; Qiu, Xinqi ; Leung, Felix W ; Jiang, Rui ; Lyu, Yanlin ; Tong, Shuangshuang ; Chen, Hao ; Luo, Ruibang ; Chen, Jianyi

Abstract:

Autism spectrum disorder (ASD) is a complex neurodevelopmental disorder for which current treatments are limited and drug development costs are prohibitive. Identifying drug targets for ASD is crucial for the development of targeted therapies. Summary-level data of expression quantitative trait loci obtained from GTEx, protein quantitative trait loci data from the ROSMAP project, and two ASD genome-wide association studies datasets were utilized for discovery and replication. We conducted a combined analysis using Mendelian randomization (MR), transcriptome-wide association studies, Bayesian colocalization, and summary-data-based MR to identify potential therapeutic targets associated with ASD and examine whether there are shared causal variants among them. Furthermore, pathway and drug enrichment analyses were performed to further explore the underlying mechanisms and summarize the current status of pharmacological targets for developing drugs to treat ASD. The protein–protein interaction (PPI) network and mouse knockout models were performed to estimate the effect of therapeutic targets. A total of 17 genes revealed causal associations with ASD and were identified as potential targets for ASD patients. Cathepsin B (CTSB) [odd ratio (OR) = 2.66 95, confidence interval (CI): 1.28–5.52, P = 8.84 × 10−3], gamma-aminobutyric acid type B receptor subunit 1 (GABBR1) (OR = 1.99, 95CI: 1.06–3.75, P = 3.24 × 10−2), and formin like 1 (FMNL1) (OR = 0.15, 95CI: 0.04–0.58, P = 5.59 × 10−3) were replicated in the proteome-wide MR analyses. In Drugbank, two potential therapeutic drugs, Acamprosate (GABBR1 inhibitor) and Bryostatin 1 (CASP8 inhibitor), were inferred as potential influencers of autism. Knockout mouse models suggested the involvement of the CASP8, GABBR1, and PLEKHM1 genes in neurological processes. Our findings suggest 17 candidate therapeutic targets for ASD and provide novel drug targets for therapy development and critical drug repurposing opportunities.

15 Apr 2024·Current Alzheimer research

Comprehensive Insights into Pathophysiology of Alzheimer's Disease: Herbal Approaches for Mitigating Neurodegeneration

Article

Author: Rathee, Sunny ; Jain, Sanjay K ; Sen, Debasis ; Patil, Umesh K ; Pandey, Vishal

Abstract::

Alzheimer's disease [AD] is a progressive neurodegenerative disorder characterized by cognitive decline, memory loss, and functional impairment. Despite extensive research, the exact etiology remains elusive. This review explores the multifaceted pathophysiology of AD, focusing on key hypotheses such as the cholinergic hypothesis, hyperphosphorylated Tau Protein and Amyloid β hypothesis, oxidative stress hypothesis, and the metal ion hypothesis. Understanding these mechanisms is crucial for developing effective therapeutic strategies. Current treatment options for AD have limitations, prompting the exploration of alternative approaches, including herbal interventions. Cholinesterase inhibitors, targeting the cholinergic hypothesis, have shown modest efficacy in managing symptoms. Blocking Amyloid β [Aβ] and targeting hyperphosphorylated tau protein are under investigation, with limited success in clinical trials. Oxidative stress, implicated in AD pathology, has led to the investigation of antioxidants. Natural products, such as Punica granatum Linn, Radix Scutellariae, and Curcuma longa have demonstrated antioxidant properties, along with anti-inflammatory effects, offering potential neuroprotective benefits. Several herbal extracts, including Ginkgo biloba, Bacopa monnieri, and Withania somnifera, have shown promise in preclinical studies. Compounds like Huperzine A, Melatonin, and Bryostatin exhibit neuroprotective effects through various mechanisms, including cholinergic modulation and anti-inflammatory properties. However, the use of herbal drugs for AD management faces limitations, including standardization issues, variable bioavailability, and potential interactions with conventional medications. Additionally, the efficacy and safety of many herbal products remain to be established through rigorous clinical trials. This review also highlights promising natural products currently in clinical trials, such as Resveratrol and Homotaurine, and their potential impact on AD progression. DHA, an omega-3 fatty acid, has shown cognitive benefits, while Nicotine is being explored for its neuroprotective effects. In conclusion, a comprehensive understanding of the complex pathophysiology of AD and the exploration of herbal interventions offer a holistic approach to managing this devastating disease. Future research should address the limitations associated with herbal drugs and further evaluate the efficacy of promising natural products in clinical settings.

News (Medical) associated with Bryostatin 1

18 Jul 2024

·www.prnewswire.com

Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury

Company holds exclusive rights to family of polyunsaturated fatty acid (PUFA) analogs New patent covers proprietary analogs in the treatment of neurodegenerative diseases NEW YORK, July 18, 2024 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced a new collaboration agreement with LSU Health New Orleans' Neuroscience Center of Excellence for pre-clinical testing of the Company's polyunsaturated fatty acid (PUFA) analogs as a treatment for spinal cord injury (SCI). The Company also announced that the US Patent and Trademark Office (USPTO) recently issued US Patent No. 12,016,837 titled 'Halogenated Esters of Cyclopropanated Unsaturated Fatty Acids for Use in the Treatment of Neurodegenerative Diseases,' covering its family of analogs. The studies will compare the analogs with Bryostatin in SCI. "We are excited to begin this new collaboration with Synaptogenix to test the regenerative properties of Bryostatin and related compounds on our preclinical model of Spinal Cord Injury," stated Dr. Nicolas Bazan, Director, Neuroscience Center of Excellence, LSU Health New Orleans. "Dr. Nicolas Bazan is a world-renowned neuroscientist with an extensive body of innovative research on neuroprotection and brain damage dating over three decades," said Dr. Alan Tuchman, Chief Executive Officer of Synaptogenix. "We look forward to a robust study of our PUFA drug prototypes at his LSU Health New Orleans neuroscience lab. We believe these assets represent a potential source for follow-on drug candidates," Dr. Tuchman added. Synaptogenix holds exclusive rights to its PUFA analogs pursuant to a licensing agreement with Cognitive Research Enterprises, Inc. (CRE), formerly known as the Blanchette Rockefeller Neurosciences Institute. "Earlier pre-clinical testing by CRE showed positive results from the PUFA analogs in slowing or reversing several neurodegenerative disease processes in Alzheimer's disease, and positive outcomes in synaptogenesis, anti-amyloid and anti-tau tangles, and prevention of neuronal death," said Dr. Daniel Alkon, President and CSO of Synaptogenix. "We are developing and patenting this class of compounds as a next-generation treatment for neurodegenerative diseases." Like Bryostatin-1, the PUFA analogs are activators of the enzyme PKC epsilon (PKC ε), but the analogs are structurally different from Bryostatin-1 and activate PKC ε at a different site on the enzyme. PKC ε activation has been shown in preclinical in vivo models to play a key role in slowing or reversing several neurodegenerative disease processes in stroke, Alzheimer's disease (AD), ALS (Lou Gehrig's disease) and spinal cord injury. About Synaptogenix Synaptogenix is a clinical-stage biopharmaceutical company that has historically worked to develop novel therapies for neurodegenerative diseases. Synaptogenix has conducted clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in Alzheimer's disease. Preclinical studies have also demonstrated bryostatin's regenerative mechanisms of action for the rare disease Fragile X syndrome, and for other neurodegenerative disorders such as multiple sclerosis, stroke, and traumatic brain injury. The U.S. Food and Drug Administration has granted Orphan Drug Designation to Synaptogenix for Bryostatin-1 as a treatment for Fragile X syndrome. Bryostatin-1 has already undergone testing in more than 1,500 people in cancer studies, thus creating a large safety data base that will further inform clinical trial designs. Additional information about Synaptogenix, Inc. may be found on its website: Forward-Looking Statements Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Such forward-looking statements are subject to risks and uncertainties and other influences, many of which the Company has no control over. There can be no assurance that the clinical program for Bryostatin-1 will be successful in demonstrating safety and/or efficacy, that the Company will not encounter problems or delays in clinical development, or that Bryostatin-1 will ever receive regulatory approval or be successfully commercialized. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Additional factors that may influence or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain adequate financing, the significant length of time associated with drug development and related insufficient cash flows and resulting illiquidity, the Company's patent portfolio, the Company's inability to expand its business, significant government regulation of pharmaceuticals and the healthcare industry, lack of product diversification, availability of the Company's raw materials, existing or increased competition, stock volatility and illiquidity, and the Company's failure to implement its business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the Securities and Exchange Commission. The Company does not undertake to update these forward-looking statements. Contact 800-811-5591 [email protected] SOURCE Synaptogenix, Inc.

Orphan DrugLicense out/in

26 Jun 2024

·www.prnewswire.com

Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis

Collaborative study will evaluate drug's potential to improve synaptic health and cognitive function in MS patients NEW YORK, June 26, 2024 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that the Food & Drug Administration (FDA) has authorized an Investigational New Drug (IND) application for Bryostatin-1 as a potential treatment for multiple sclerosis (MS). The fully-funded, open-label clinical trial will be held and managed at Cleveland Clinic Neurological Institute's Mellen Center for Multiple Sclerosis. The study will utilize state-of-the-art 7-tesla (7T) magnetic resonance imaging (MRI) technology to identify biomarkers for evaluating Bryostatin-1's impact on the brain. Robert Fox, M.D., Vice-Chair for Research, Neurological Institute, Cleveland Clinic, and principal investigator for the Bryostatin-1 trial commented, "Our study will apply state-of-the-art MRI technology together with behavioral and cognitive measures to evaluate treatment with investigational Bryostatin-1. Research and development of this drug could yield potential benefits for patients with MS." "While cognitive decline is broadly recognized as a prevalent symptom of multiple sclerosis, the mechanisms underlying cognitive impairment remain obscure and inadequately studied in clinical trials," said Dr. Alan Tuchman, Chief Executive Officer of Synaptogenix. "We seek to address this unmet need, with minimal expense, and look forward to launching our effort by enrolling/dosing our first patient in the near future." Bryostatin-1 is a small molecule that works by activating protein kinase C (PKC) enzymes required for maintaining synapse health and is involved in learning and memory. The therapy may also enhance anti-inflammatory efficacy to prevent degradation of the insulating sheath around nerve fibers. "Bryostatin-1 has been shown in preclinical studies, through its activation of PKC enzymes, to prevent synapse loss and neuronal death, to ameliorate inflammation, and reduce the onset of neurologic deficits," added Daniel Alkon, M.D., President and Chief Scientific Officer. "These preclinical data suggest that Bryostatin-1 has promising potential as a therapeutic agent for MS and perhaps more so for progressive forms of MS." With a strong balance sheet including approximately $26.3 million in cash as of March 31, 2024, the Company's Phase 1 MS trial is fully-funded. The Company maintains a relatively low cash burn rate and ample resources to support continued development of Bryostatin-1 for MS and other indications, as well as to pursue research on other innovative assets and/or the potential acquisitions of asset rights. About Synaptogenix Synaptogenix is a clinical-stage biopharmaceutical company that has historically worked to develop novel therapies for neurodegenerative diseases. Synaptogenix has conducted clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in Alzheimer's disease. Preclinical studies have also demonstrated bryostatin's regenerative mechanisms of action for the rare disease Fragile X syndrome, and for other neurodegenerative disorders such as multiple sclerosis, stroke, and traumatic brain injury. The U.S. Food and Drug Administration has granted Orphan Drug Designation to Synaptogenix for Bryostatin-1 as a treatment for Fragile X syndrome. Bryostatin-1 has already undergone testing in more than 1,500 people in cancer studies, thus creating a large safety data base that will further inform clinical trial designs. Additional information about Synaptogenix, Inc. may be found on its website: Forward-Looking Statements Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Such forward-looking statements are subject to risks and uncertainties and other influences, many of which the Company has no control over. There can be no assurance that the clinical program for Bryostatin-1 will be successful in demonstrating safety and/or efficacy, that the Company will not encounter problems or delays in clinical development, or that Bryostatin-1 will ever receive regulatory approval or be successfully commercialized. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Additional factors that may influence or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain adequate financing, the significant length of time associated with drug development and related insufficient cash flows and resulting illiquidity, the Company's patent portfolio, the Company's inability to expand its business, significant government regulation of pharmaceuticals and the healthcare industry, lack of product diversification, availability of the Company's raw materials, existing or increased competition, stock volatility and illiquidity, and the Company's failure to implement its business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the Securities and Exchange Commission. The Company does not undertake to update these forward-looking statements. Contact 800-811-5591 [email protected] SOURCE Synaptogenix, Inc.

INDOrphan DrugPhase 1

07 May 2024

·www.prnewswire.com

Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug Discovery

Proposed Schedule III drug classification expected to de-risk Cannasoul's cannabis research and potential regulatory pathways NEW YORK, May 7, 2024 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today applauds the reported move by the U.S. Drug Enforcement Agency (the "DEA") to recommend reclassifying cannabis as a Schedule III drug, and announces potential benefits of the rescheduling to its partner Cannasoul Analytics ("Cannasoul"), founded by the Technion-Israel Institute of Technology, in its discovery of cannabis-based therapeutics. As reported in the press on April 30, 2024, the DEA will move to reclassify cannabis from a Schedule I drug to a Schedule III under the Controlled Substance Act on recommendation by the U.S. Department of Health and Human Services. The reclassification would be the most significant change in cannabis policy in 50 years. The rescheduling of cannabis would significantly de-risk drug development for cannabis and derivatives and enable companies to utilize well-defined pathways for non-clinical and clinical testing, without specialized license requirements. Reclassification would also enable cannabis drug developers to provide straightforward estimates on timing and costs through easier access to manufacturing facilities and research sites for animal and human testing. "We are pleased to learn about the DEA's proposed rescheduling, which, if adopted as a final rule pursuant to the typical rulemaking process, we believe would bring substantial benefits for drug discovery companies engaged in clinical development for cannabis-based therapeutics," said Dr. Alan Tuchman, Chief Executive Officer of Synaptogenix. "Schedule III classification would more closely align clinical development for such therapies with the regulatory pathways for non-controlled drugs. As clinical development becomes more mainstream, we believe our partnership with Cannasoul has the potential to unlock even greater value from owned assets and intellectual property as well as our accessibility to the resources of Cannasoul's founder, the Technion-Israel Institute of Technology." The partnership with Cannasoul is exploring potential targets for cannabinoid-based therapeutics in multiple indications including solid tumors, migraine headache, inflammatory bowel disease, and estrogen-related diseases. Any future clinical development program involving any such targets is expected to be conducted in the United States. About the Synaptogenix/Cannasoul Partnership Synaptogenix acquired a 25% stake in Cannasoul in November 2023 in support of research and development cannabinoid-based therapeutics. Cannasoul is known in the field of analytical method development for pharmaceutical and botanical research and development, and it holds unique expertise in the field of cannabis and psilocybin research through its analysis of more than 100 cannabinoids and 100 terpenes. Cannasoul is founded by the Technion Research & Development Foundation, the commercialization arm of the Technion-Israel Institute of Technology, Israel's largest center of applied research and a major source of innovation driving the Israeli economy. About Synaptogenix Synaptogenix is a clinical-stage biopharmaceutical company that has historically worked to develop novel therapies for neurodegenerative diseases. Synaptogenix has conducted clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in Alzheimer's disease. Preclinical studies have also demonstrated bryostatin's regenerative mechanisms of action for the rare disease Fragile X syndrome, and for other neurodegenerative disorders such as multiple sclerosis, stroke, and traumatic brain injury. The U.S. Food and Drug Administration has granted Orphan Drug Designation to Synaptogenix for Bryostatin-1 as a treatment for Fragile X syndrome. Bryostatin-1 has already undergone testing in more than 1,500 people in cancer studies, thus creating a large safety data base that will further inform clinical trial designs. Additional information about Synaptogenix, Inc. may be found on its website: Forward-Looking Statements Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Such forward-looking statements are subject to risks and uncertainties and other influences, many of which the Company has no control over. There can be no assurance that the clinical program for Bryostatin-1 will be successful in demonstrating safety and/or efficacy, that the Company will not encounter problems or delays in clinical development, or that Bryostatin-1 will ever receive regulatory approval or be successfully commercialized. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Additional factors that may influence or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain adequate financing, the significant length of time associated with drug development and related insufficient cash flows and resulting illiquidity, the Company's patent portfolio, the Company's inability to expand its business, significant government regulation of pharmaceuticals and the healthcare industry, lack of product diversification, availability of the Company's raw materials, existing or increased competition, stock volatility and illiquidity, and the Company's failure to implement its business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the Securities and Exchange Commission. The Company does not undertake to update these forward-looking statements. Contact 800-811-5591 [email protected] SOURCE Synaptogenix, Inc.

Orphan DrugAcquisition

100 Deals associated with Bryostatin 1

External Link

KEGG	Wiki	ATC	Drug Bank
-	Bryostatin 1	-	DB11752

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Alzheimer Disease	Phase 2	US	Synaptogenix, Inc.	01 Nov 2015
B-Cell Lymphoma	Phase 2	US	National Institute on Aging	01 Jul 2004
Refractory Indolent Non-Hodgkin Lymphoma	Phase 2	US	National Institute on Aging	01 Jul 2004
Diffuse Large B-Cell Lymphoma	Phase 2	US	National Cancer Institute	01 Mar 2003
Low Grade B-Cell Non-Hodgkin's Lymphoma	Phase 2	US	National Cancer Institute	01 Mar 2003
Mantle cell lymphoma recurrent	Phase 2	US	National Cancer Institute	01 Mar 2003
Marginal zone lymphoma recurrent	Phase 2	US	National Cancer Institute	01 Mar 2003
Recurrent Grade 3a Follicular Lymphoma	Phase 2	US	National Cancer Institute	01 Mar 2003
Small Lymphocytic Lymphoma	Phase 2	US	National Cancer Institute	01 Mar 2003
Acinar Cell Carcinoma	Phase 2	US	National Cancer Institute	01 Mar 2002

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04538066 (CTgov)	Phase 2	Alzheimer Disease	122	Bryostatin 1 (Bryostatin 1)	pncrvxafah(wtwgpbemdq) = uuylpxrtpk lcznlzpwwc (wkjevvfkyp, xmhzqzhcll - yxufvxpxbb) View more	-	31 Jul 2024
				Placebo (Placebo)	pncrvxafah(wtwgpbemdq) = igjbvupqmx lcznlzpwwc (wkjevvfkyp, awfwelbmgn - vmjhlqhebu) View more
NCT04538066 (Literature) Manual	Phase 2	Alzheimer Disease	122	Bryostatin 1	eqbhofsexq(psrvrswcuk) = vnfhdsnirl dtgnvwnthy (ygkpphbphf, 1.56) View more	Positive	19 Sep 2023
				Placebo	eqbhofsexq(psrvrswcuk) = iwtvxtgosv dtgnvwnthy (ygkpphbphf, 1.51) View more
NCT03560245 (CTgov)	Phase 2	Alzheimer Disease	108	Bryostatin (Bryostatin 20µg)	kcydiveoah(uuauklhuzp) = xkuoakpqfb mbrlvexcof (jwvuwgnmni, jjaffgbfpy - nwyhmihjfc) View more	-	01 Oct 2020
				Placebo (Placebo)	kcydiveoah(uuauklhuzp) = bmndggsjpq mbrlvexcof (jwvuwgnmni, smndggofkg - xfewtljvkz) View more
NCT02431468 (CTgov)	Phase 2	Alzheimer Disease	147	Bryostatin 1 (Bryostatin 1 20ug)	ewlgnelstq(lpmwydnuha) = ndobmyyext mwsydxodrl (uezwbiclht, tgixihpbqj - fjpilrdfhr) View more	-	06 Jul 2018
				Bryostatin 1 (Bryostatin 1 40ug)	ewlgnelstq(lpmwydnuha) = xgpuigdcms mwsydxodrl (uezwbiclht, gtadwldfwx - hijexmrgkr) View more
NCT02221947 (CTgov)	Phase 1/2	Alzheimer Disease	9	Bryostatin 1 (Bryostatin 1)	ydfqhuyggg(wmojmsxcak) = ybwsvftcey vzfemjdiyf (cbozryuvbd, xxetsarseu - mkwsguyrzf) View more	-	21 Apr 2016
				Placebo (Placebo)	ydfqhuyggg(wmojmsxcak) = wzlprwplen vzfemjdiyf (cbozryuvbd, vqjjuaqcwu - jtovwpjjvu) View more
NCT00031694 (CTgov)	Phase 2	Acinar Cell Carcinoma \| Pancreatic Ductal Adenocarcinoma	19	bryostatin 1+paclitaxel	tggokfdhly(zkziiscjpo) = nnniyhjwco mcziqdoaqr (sttcibmhro, biuyjpuaxe - lfazsjhdqr) View more	-	21 Apr 2015
NCT00006389 (CTgov)	Phase 2	Metastatic Gastric Carcinoma	12	laboratory biomarker analysis+bryostatin 1+cisplatin	homhgmzjfg(sjzkkkxdhx) = tnjrbnhxqt xrnoqvsggy (ajgretxjzc, vnoxruxknq - ihuduanclj) View more	-	01 Oct 2014
SFN2008	Not Applicable	-	-	Bryostatin-1	bccjpeulvm(mbdnkhtors) = zfblfofyhq rkdobbvrzb (pigslvgzxc ) View more	-	16 Nov 2008
				Normal Saline	ejvdtkekve(xpvtjxjlpw) = bloaqmsxgo hyemahmbjp (gzsziqqgoe ) View more
SFN2008	Not Applicable	-	-	Bryostatin	lnlnaxwsgn(lkccxbhfyo) = dlapatxixk vztmdudzjf (lzgmrwaywt )	-	16 Nov 2008
				bryostatin (GABA signaling blockade)	lnlnaxwsgn(lkccxbhfyo) = pdazbkucoi vztmdudzjf (lzgmrwaywt )
NCT00004144 (Pubmed \| Clin Cancer Res)	Phase 1	Solid tumor \| Advanced cancer	36	Bryostatin 1	nbqnpeotyc(pyfxlsemhw) = tfblpauvmn yjavxqipki (ttciorbgzm ) View more	-	01 Dec 2006
				Gemcitabine	nbqnpeotyc(pyfxlsemhw) = rszytpzghn yjavxqipki (ttciorbgzm )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis